Gentium Adds Seasoned Pharmaceutical Veteran Malcolm Sweeney to Board of Directors

Gentium S.p.A. (Nasdaq: GENT) announced the election of Mr.
Malcolm Sweeney to the Company's Board of Directors. Mr. Sweeney was
formerly the Head of Financial Reporting and Accounting for the Pharma
Division of Novartis, AG. Prior to Novartis Mr. Sweeney worked for IMS
Health Inc., (formerly IMS International), a provider of market
intelligence to the pharmaceutical and healthcare industries. He held
positions of Corporate Controller and Senior Director of Finance for
IMS, as well Leader of European Shared Services for Dun and Bradstreet
(former owner of IMS). From 1974 to 1990, he held a variety of finance
positions for a number of Divisions of General Electric. Mr. Sweeney
resides in the U.K., is a chartered accountant, admitted to the
Institute of England & Wales in 1974 when working for KPMG (formerly
Peat, Marwick, Mitchell and Co.). He received a Bachelor of Science in
Physics, Economics and Philosophy from the University of Exeter in
1970.

"Malcolm is extremely well-recognized for his expertise and
leadership in the pharmaceutical industry," said Dr. Laura Ferro
Chairman and CEO of Gentium. "He brings to Gentium an exceptionally
well-rounded background of financial, marketing, and general
management experience from his years within the pharmaceutical
industry."

About Gentium

Gentium S.p.A. is a biopharmaceutical company focused on the
research, discovery and development of drugs derived from DNA
extracted from natural sources, and drugs that are synthetic
derivatives, to treat and prevent a variety of vascular diseases and
conditions related to cancer and cancer treatments. Defibrotide, the
Company's lead product candidate in the U.S., is an investigational
drug that has been granted Orphan Drug status by the U.S. Food and
Drug Administration to prevent and to treat VOD and Fast Track
designation for the treatment of severe VOD in recipients of stem cell
transplants.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some
cases, you can identify these statements by forward-looking words such
as "may," "might," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential" or "continue," the
negative of these terms and other comparable terminology. These
statements are not historical facts but instead represent the
Company's belief regarding future results, many of which, by their
nature, are inherently uncertain and outside the Company's control. It
is possible that actual results may differ, possibly materially, from
those anticipated in these forward-looking statements. For a
discussion of some of the risks and important factors that could
affect future results, see the discussion in our Form 20F filed with
the Securities and Exchange Commission under the caption "Risk
Factors."